Last reviewed · How we verify
antipsychotics
At a glance
| Generic name | antipsychotics |
|---|---|
| Also known as | Seroquel, Geodon, Zyprexa, Abilify |
| Sponsor | Janssen-Cilag, S.A. |
| Modality | Small molecule |
| Therapeutic area | Neuroscience |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
- Incentives and Long-Acting Injectable Adherence After Involuntary Hospitalization (NA)
- Immune Mechanisms of Antipsychotic Treatment Response
- Cue-based Intervention in Prospective Memory and Medication Adherence. (NA)
- Cerebellum-based Imaging Neural Markers for Antipsychotic Response
- Psychiatric Multi-omics and Neuroimaging Project
- Cognitive Impairment Characteristics and Biological Mechanisms in Untreated Severe Mental Illness
- Medication Adherence in Severe Mental Illness: a Promotion Program (NA)
- Pharmacist-led Interventions in Psychiatric Patients (NA)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- antipsychotics CI brief — competitive landscape report
- antipsychotics updates RSS · CI watch RSS
- Janssen-Cilag, S.A. portfolio CI